Certara, Inc. (NASDAQ:CERT) Receives Average Rating of “Hold” from Brokerages

Certara, Inc. (NASDAQ:CERT) has been assigned an average recommendation of “Hold” from the twelve analysts that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $8.2778.

A number of research analysts have recently weighed in on the company. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a report on Wednesday, August 5th. Barclays upped their price target on Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. Morgan Stanley lowered their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Stephens dropped their price objective on Certara from $10.00 to $9.00 and set an “overweight” rating on the stock in a research note on Tuesday, May 12th. Finally, Craig Hallum cut their price objective on shares of Certara from $10.00 to $8.00 and set a “hold” rating on the stock in a report on Tuesday, May 12th.

Certara Stock Performance

NASDAQ:CERT opened at $8.35 on Monday. The company has a debt-to-equity ratio of 0.30, a current ratio of 2.55 and a quick ratio of 2.55. Certara has a one year low of $4.45 and a one year high of $13.88. The company has a market cap of $1.27 billion, a PE ratio of -18.56 and a beta of 1.44. The firm has a 50-day moving average of $7.37 and a 200-day moving average of $6.47.

Certara (NASDAQ:CERT) last announced its quarterly earnings results on Tuesday, August 4th. The company reported $0.08 earnings per share for the quarter, missing the consensus estimate of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The business had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same period in the previous year, the business posted $0.07 EPS. Certara’s revenue was down 10.8% compared to the same quarter last year. As a group, equities research analysts expect that Certara will post 0.22 EPS for the current fiscal year.

Institutional Investors Weigh In On Certara

Institutional investors have recently added to or reduced their stakes in the company. AQR Capital Management LLC purchased a new position in shares of Certara in the 1st quarter worth approximately $259,000. Goldman Sachs Group Inc. lifted its holdings in Certara by 65.6% during the first quarter. Goldman Sachs Group Inc. now owns 228,996 shares of the company’s stock worth $2,267,000 after acquiring an additional 90,724 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Certara by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 299,528 shares of the company’s stock worth $2,965,000 after acquiring an additional 35,954 shares during the period. Jane Street Group LLC boosted its position in Certara by 17.1% in the first quarter. Jane Street Group LLC now owns 277,054 shares of the company’s stock worth $2,743,000 after purchasing an additional 40,463 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Certara by 29.3% in the second quarter. JPMorgan Chase & Co. now owns 93,057 shares of the company’s stock worth $1,089,000 after purchasing an additional 21,099 shares during the last quarter. 73.96% of the stock is owned by institutional investors.

Certara Company Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.